ISSUE 1388
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Transcatheter aortic-valve replacement (TAVR), a procedure in which a prosthetic valve is inserted into the aortic annulus by a catheter, has been approved by the FDA as an alternative to surgical aortic-valve replacement for patients with severe symptomatic aortic stenosis who are considered inoperable.
AORTIC STENOSIS — Untreated patients with symptomatic aortic stenosis have a 50% mortality rate within 2 years. Some patients with severe aortic stenosis are not candidates for surgery because of advanced age, left ventricular dysfunction or other illnesses.1 Others undergo surgery despite a high operative risk.
THE VALVE — The Edwards SAPIEN transcatheter heart valve (Edwards Lifesciences) approved in the US is a trileaflet valve constructed from bovine pericardium and mounted in a balloon-expandable stainless steel frame. The
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1388b
Electronic, downloadable article - $45